These results should be considered in addition to, not as a substitute for, results reported in accordance with U.S. GAAP. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the unsubscribe section below. Exhibits 21.1 CATALENT PHARMA SOLUTIONS, INC. SUBSIDIARIES As of June 30, 2013 NAME (STATE OF ORGANIZATION) WHOLLY OWNED SUBSIDIARIES OF CATALENT PHARMA SOLUTIONS, INC. A comprehensive toolkit that offers a developability assessment specific to protein degraders to help identify orally bioavailable candidates and leverage an array of specialized capabilities to select the right formulation to efficiently get to clinic and beyond. Reconciliation of Net Earnings to Adjusted Net Income*, (Unaudited; in millions, except per share data), Discrete income tax (benefit)/expense items (4). Segment EBITDA margin was 27.0% in the first quarter of fiscal 2021 compared to 25.5% in the first quarter of the prior year. Catalent, Inc. and Subsidiaries. For a more detailed discussion of these and other factors, see the information under the caption Risk Factors in Catalents Annual Report on Form 10-K for the fiscal year ended June 30, 2020, filed August 31, 2020. Catalent believes that Adjusted Net Income/(Loss) and Adjusted Net Income/(Loss) per share provides investors with a useful tool for assessing the comparability between periods of its ability to generate cash from operations available to its stockholders. SOMERSET, N.J.--(BUSINESS WIRE)-- Scherer Corporation (Headquarters: Troy, Michigan). 1Y -0.62% ( 1D) About CTLT Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. For a more detailed discussion of these and other factors, see the information under the caption Risk Factors in Catalents Annual Report on Form 10-K for the fiscal year ended June 30, 2020, filed August 31, 2020. Reconciliation of Net Earnings to EBITDA from Operations and Adjusted EBITDA*, Acquisition, integration, and other special items, Foreign exchange loss/(gain) (included in other, net). As changes in exchange rates are an important factor in understanding period-to-period comparisons, Catalent believes the presentation of results on a constant-currency basis in addition to reported results helps improve investors ability to understand its operating results and evaluate its performance in comparison to prior periods. Selected Segment Financial Data The current debt structure does not include any significant maturity until 2026. Segment EBITDA margin was 24.5% in the third quarter of fiscal 2021, compared to 24.8% in the third quarter of the prior year. Overall organic growth was 20%. The investment includes new Zydis lines; changes to one of their facilities in Swindon, UK; and a custom suite for commercial equipment. Segment EBITDA margin was 33.1% in the third quarter of fiscal 2021 compared to 20.8% in the third quarter of the prior year. Some of the factors that could cause actual results to differ include, but are not limited to, the following: the current or future effects of the COVID-19 pandemic on Catalent's and its clients' businesses; participation in a highly competitive market and increased competition that may adversely affect Catalents business; demand for its offerings, which depends in part on its customers research and development and the clinical and market success of their products; product and other liability risks that could adversely affect Catalents results of operations, financial condition, liquidity and cash flows; failure to comply with existing and future regulatory requirements; failure to provide quality offerings to customers could have an adverse effect on Catalents business and subject it to regulatory actions and costly litigation; problems providing the highly exacting and complex services or support required; global economic, political and regulatory risks to Catalents operations; inability to enhance existing or introduce new technology or service offerings in a timely manner; inadequate patents, copyrights, trademarks and other forms of intellectual property protections; fluctuations in the costs, availability, and suitability of the components of the products Catalent manufactures, including active pharmaceutical ingredients, excipients, purchased components and raw materials; changes in market access or healthcare reimbursement in the United States or internationally; fluctuations in the exchange rate of the U.S. dollar against other currencies, including as a result of the U.K.s exit from the European Union; adverse tax legislative or regulatory initiatives or challenges or adjustments to Catalents tax positions; loss of key personnel; risks generally associated with information systems; inability to complete any future acquisitions or other transactions that may complement or expand its business or divest of non-strategic businesses or assets and difficulties in successfully integrating acquired businesses and realizing anticipated benefits of such acquisitions; risks associated with timely and successfully completing, and correctly anticipating the future demand predicted for, capital expansion projects at existing facilities, offerings and customers products that may infringe on the intellectual property rights of third parties; environmental, health and safety laws and regulations, which could increase costs and restrict operations; labor and employment laws and regulations or labor difficulties, which could increase costs or result in operational disruptions; additional cash contributions required to fund Catalents existing pension plans; substantial leverage that may limit its ability to raise additional capital to fund operations and react to changes in the economy or in the industry; and exposure to interest-rate risk to the extent of its variable-rate debt preventing it from meeting its obligations under its indebtedness. Join the global drug development and delivery leader that puts Patient First at the center of our work every day. These statements are based on current expectations of future events. Scherer End 60 Year Joint Venture", "Catalent's Brazilian acquisition supports global softgel strategy", "Catalent Issues Initial Public Offering", "Catalent Acquires Micron Technologies, Adds Particle Engineering Capabilities to Portfolio", "Catalent Buys Pharmatek and Lands Spray Drying Technology", "Catalent targets biologics with Cook Pharmica acquisition", "Catalent extends expansion with $133M deal for Juniper Pharmaceuticals", "Catalent Names Alessandro Maselli President and Chief Operating Officer", "Catalent Invests in Zydis Ultra Commercialization", "Wellness products take off in the growing recreational cannabis market", "Catalent to Buy Paragon Bioservices for $1.2 Billion", "Catalent's new prize, Paragon, adding capacity to make Sarepta gene therapies", "Paragon growing quickly toward 1,000 employees after Catalent acquisition", "Bristol-Myers offloads manufacturing plant to Catalent", "Catalent laying out $315M to snatch another gene therapy CDMO", "Catalent adds to regenerative therapy portfolio with $315m acquisition", "Pfizer to outsource some drug production, focus on coronavirus vaccine", "AstraZeneca Picks Catalent for Packaging, Supplying Potential COVID-19 Vaccine", "Moderna Is the Latest Coronavirus Vaccine Partner for Catalent", "Vaccine makers face biggest medical manufacturing challenge in history", "AstraZeneca taps Catalent Inc. to manufacture Covid-19 vaccine candidate in Maryland", "Manufacturer to help develop potential Covid treatment at St. Pete facility", "Catalent Finalizes RheinCell Therapeutics Acquisition", "WSJ News Exclusive | Catalent to Buy Supplement Maker Bettera Holdings for $1 Billion", "Catalent's Momentum Continues with Up to 600 New Jobs Being Added", "Catalent Announces $12 Million Expansion Program at Kansas City Facility", "Catalent inks deal to manufacture Sarepta's DMD gene therapy", "Sarepta marches forward with its potential DMD gene therapy and an expanded Catalent manufacturing deal", "Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate", https://en.wikipedia.org/w/index.php?title=Catalent&oldid=1138334559, Drug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting, This page was last edited on 9 February 2023, at 03:14. Calculation of Net Leverage Ratio $37.00 (As of Thursday Closing) General Information Description Catalent is a contract development and manufacturing organization, or CDMO. Segment EBITDA margin was 28.2% in the first quarter of fiscal 2021 compared to 19.0% in the first quarter of the prior year. As a result, Catalent does not believe that a U.S. GAAP reconciliation would provide meaningful supplemental information about its outlook. 2020. Catalent Company Profile - Office Locations, Competitors, Revenue Catalent (NYSE:CTLT) - Stock Price, News & Analysis - Simply Wall St Segment EBITDA in the first quarter of fiscal 2021 was $21.4 million, a decrease of 23% as reported, or 26% in constant currency, compared to the first quarter a year ago. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. SOMERSET, N.J. - November 16, 2020 Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has completed the acquisition of Bone Therapeutics' cell therapy manufacturing subsidiary, Skel. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopaedic conditions, targeting markets with large unmet medical needs and limited innovation. An experienced partner, Catalent Cell & Gene Therapy has worked with industry leaders across 70+ clinical and commercial programs. Exelixis and Catalent Enter into Collaboration, License, and Exclusive Catalent presents EBITDA from operations in order to provide supplemental information that it considers relevant for the readers of its consolidated financial statements, and such information is not meant to replace or supersede U.S. GAAP measures. More products. (ARGENTINA) 4. Catalent evaluates the performance of its segments based on segment earnings before non-controlling interest, other (income)/expense, impairments, restructuring costs, interest expense, income tax expense/(benefit), and depreciation and amortization (segment EBITDA). Catalent is raising its previously issued guidance to reflect first quarter performance and to account for higher net underlying demand, including increased demand related to COVID-19 treatments and vaccines, partially offset by lower demand attributed to the effects of the pandemic in some offerings. Catalent evaluates the performance of its segments based on segment earnings before non-controlling interest, other (income) expense, impairments, restructuring costs, interest expense, income tax expense (benefit), and depreciation and amortization (segment EBITDA). Under the terms of the agreement, Catalent has purchased the shares of SCTS, previously held by Bone Therapeutics, and a purpose-built CGxP facility of approximately 41,000 square-foot (3,800 square-meter), including its related quality control and product development laboratories, warehouse, grade C and B cleanrooms and equipment as well as land for further development. [18] In July 2018, Catalent extended their work with Juniper Pharmaceuticals with a $133 million deal. After accounting for the net earnings attributable to holders of Catalents Series A convertible preferred stock, net earnings attributable to common shareholders were $217.1 million, or $1.27 per basic share, compared to net earnings attributable to common shareholders of $11.8 million, or $0.08 per basic share, in the third quarter a year ago. Catalent Commences Construction of New $20M Expansion to its Clinical Supply Facility in Schorndorf, Germany; Catalent Expert to Chair Panel Discussion on Integrated Clinical Drug Development Partnerships; VIEW ALL NEWS. [14], In November 2014, Catalent announced it had acquired Micron Technologies, a provider of particle size engineering technologies. This represents an increase of 48% as reported, and an increase of 44% on a constant-currency basis. (4) Discrete period income tax expense/(benefit) items are unusual or infrequently occurring items, primarily including: changes in judgment related to the realizability of deferred tax assets in future years, changes in measurement of a prior-year tax position, deferred tax impact of changes in tax law, and purchase accounting. Other non-current assets, including intangible assets, LIABILITIES, REDEEMABLE PREFERRED STOCK, AND SHAREHOLDERS' EQUITY, Current portion of long-term obligations and other short-term borrowings, Long-term obligations, less current portion, Total liabilities, redeemable preferred stock, and shareholders' equity. All statements other than statements of historical fact, are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Bone Therapeutics subsidiary and its facility, which is next to Catalents existing cell therapy site, will allow Catalent to expand its industry-leading cell therapy capabilities and advanced clinical and commercial supply, and create an integrated European center of excellence in cell therapy. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Catalent, Inc. (NYSE: CTLT), an S&P 500 company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. SIGN UP NOW TO STAY CURRENT WITH THE LATEST NEWS AND INSIGHTS, Catalent Completes Acquisition of Cell Therapy Manufacturing Facility from Bone Therapeutics, By using this website you understand and accept that Catalent tracks your website activities to be able to offer you a more tailored response or information to meet your requirements, and that your personal data will be held in accordance with our, Copyright 2023, Catalent, Inc - All Rights Reserved, Copyright 2020, Catalent, Inc - All Rights Reserved, Highly Potent Active Pharmaceutical Ingredients. Ongoing elevated demand across our drug product, drug substance and cell and gene therapy offerings, as well as new demand related to potential COVID-19 vaccines and treatments, were partially offset by headwinds in our Softgel and Oral Technologies and Oral and Specialty Delivery segments, said John Chiminski, Chair and Chief Executive Officer of Catalent, Inc. [23] The deal was completed in May 2019 and included an agreement with Sarepta Therapeutics, a gene therapy manufacturer. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent does not undertake to update any forward-looking statement as a result of new information or future events or developments except to the extent required by law. Catalents definition of Adjusted Net Income (Loss) may not be the same as similarly titled measures used by other companies. Catalent uses results on a constant-currency basis as one measure to evaluate its performance. Mr. Barber is the Chief Diversity Officer (CDO) for General Electric Company. After submitting your request, you will receive an activation email to the requested email address. About the company Rewards Price-To-Earnings ratio (16.6x) is below the Pharmaceuticals industry average (19.1x) Earnings are forecast to grow 55.83% per year [39], In October 2022, Catalent announced a $12M expansion at a Kansas City, MO facility. Catalent CTS (Kansas City), LLC operates as a subsidiary of Catalent, Inc. digitGaps report on Catalent CTS Kansas City LLC delivers a detailed in-depth and comprehensive insights of the company, its history, corporate strategy, its businesses and structures, and company operations by examining its performance in local market and global economy.. More products. The integration of our manufacturing subsidiary into Catalent, one of the premier contract manufacturers in the cell therapy space, significantly increases our operational flexibility.
Wurth Baer Supply Vernon Hills,
The Glen House Sunday River,
Mobile Homes For Sale Phoenix,
Odin Infinity Humidity,
Letter Earrings, Dangle,
Articles C